Aligos Q2 Loss Narrows to $1.5M, but Cash Runs Out by Year-End
ALGS is trading near its 52-week low of $3.98 (14% above the low).
Summary
Aligos narrowed its Q2 loss to $1.5M on $27.8M in licensing revenue, but cash runway only extends into Q4 2026, triggering a going concern warning. The company needs immediate financing to continue operations.
Key Events · Earnings and Guidance · ALGS
-
Q2 Loss Narrows to $1.5M
Net loss improved to $1.5M from $15.9M a year ago, driven by $27.8M in licensing revenue from the Amoytop deal for pevifoscorvir sodium.
-
Cash Runway Only Into Q4 2026
Cash, equivalents and investments totaled $30.4M as of June 30, 2026, providing funding only into Q4 2026 and triggering a going concern warning.
-
Going Concern Warning
The company states its cash is insufficient to fund operations beyond Q4 2026, requiring immediate financing to continue as a going concern.
-
Phase 2 B-SUPREME Enrollment Complete
Enrollment completed with 131 HBeAg+ and 114 HBeAg- participants; topline data expected in late Q3 2027, well beyond current cash runway.
Analysis · ALGS · Life Sciences
A dramatically improved Q2 net loss of $1.5 million was driven by $27.8 million in licensing revenue from the pevifoscorvir sodium deal with Amoytop. Yet cash and equivalents of $30.4 million as of June 30, 2026, provide runway only into Q4 2026, triggering a going concern warning. Immediate financing is needed to continue operations. On the pipeline front, enrollment completed in the Phase 2 B-SUPREME study for pevifoscorvir sodium, with topline data expected in late Q3 2027 — a timeline that extends well beyond the current cash runway. The $3 million milestone from Amoytop's IND approval for ALG-170675 provides a small near-term boost, but the overriding concern is survival to reach key data readouts.
At the time of this filing, ALGS was trading at $4.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.3M. The 52-week trading range was $3.98 to $13.69. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.